NCT03565159已完成4 期
Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 214
- 试验地点
- 23
- 主要终点
- Primary - Time to Event
研究概览
简要总结
The VACIRiSS trial is a phase-IV, multi-centre placebo controlled randomised trial of conjugate pneumococcal vaccine in adult sepsis survivors.
详细描述
The aim of VACIRiSS trial is to evaluate the immunogenicity and heterologous effects of single dose 13-valent conjugate pneumococcal vaccine (PCV-13) in preventing infection related rehospitalisation in sepsis survivors and to collect outcome event data with necessary precision to inform future definitive trial design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who meet all the following inclusion criteria are eligible to participate in the trial.
- •Male or female adult patients aged 18 years or older on the date of screening for the trial
- •Registered with a General Practitioner
- •Reason for admission to intensive care unit or high dependence unit (HDU) was sepsis
- •Clinical condition has improved and the patient is ready for step down to HDU or ward based care in the next 24 - 48 hours
- •Provision of written informed consent by the patient OR by patient's Legal Representative OR Professional Consultee.
排除标准
- •Patients who meet one or more of the following will be excluded from the trial.
- •Core temperature ≥38.0°C within the past 24 hours prior to study IMP administration. As with other vaccines, the administration of Prevenar 13 should be postponed in subjects suffering from acute, severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.
- •Hypersensitivity reaction (e.g., anaphylaxis) to any component of Prevenar 13 or any diphtheria toxoid-containing vaccine.
- •Recent vaccination defined as any vaccination administered to subjects within 7 days of enrolment.
- •Pregnant and lactating women.
- •Limitations of care set including not for resuscitation, not for readmission to critical care.
- •Residence in a nursing home, long-term care facility, or other institution, or requirement of semiskilled nursing care. (An ambulatory subject who was a resident of a retirement home or village is eligible for the trial.)
- •As the IMP is administered intra muscularly, coagulopathy defined as platelet count less than 50 x 109/L and/or International Normalized Ratio (INR) greater than 1.
- •For this exclusion criteria bloods taken within 72 hours of screening are valid. If these standard of care blood results are not available, then these should form part of the screening bloods for assessing eligibility.
- •Splenectomy (previous or in the current admission)
- •Diagnosis of pneumococcal sepsis in the current admission
- •APACHE II score defined Immune deficiency or suppression, defined as presence of 1 or more of the following conditions:
- •Documented human immunodeficiency virus (HIV) infection at any time-point pre-trial. If previous results are not available and/or current admission is not due to HIV infection, these patients do not need new testing and are considered eligible for the trial.
- •leukaemia (presence defined as having been treated by or been eligible for treatment by radiotherapy and/or chemotherapy within the last 5 years)
- •lymphoma (presence defined as having been treated by or been eligible for treatment by radiotherapy and/or chemotherapy within the last 5 years) Hodgkin disease (presence defined as having been treated by or been eligible for treatment by radiotherapy and/or chemotherapy within the last 5 years)
- •multiple myeloma (presence defined as having been treated by or been eligible for treatment by radiotherapy and/or chemotherapy within the last 5 years)
- •malignancy (defined as presence of any malignancy that had been treated by or had been eligible for treatment by radiotherapy and/or chemotherapy within the last 5 years)
- •chronic renal failure (defined as receipt of renal dialysis or transplant) or nephrotic syndrome
- •receipt of immunosuppressive therapy, including steroids, within 3 months of study vaccine administration (For corticosteroids, prednisone or equivalent 0.5 mg/kg/day for 14 days or longer. Inhaled, intra- articular, and topical steroids are not considered immunosuppressive).
- •Receipt of an organ or bone marrow transplant with ongoing immunosuppressive medications. Failed previous transplant patients not currently on immunosuppression are eligible.
结局指标
主要结局
Primary - Time to Event
时间窗: Up to 365 days
Comparison of the time taken for infection related rehospitalisation or death between intervention and control arms.
次要结局
- Secondary - Precision Estimates(Up to 365 days)
研究者
研究点 (23)
Loading locations...
相似试验
已完成
4 期
Vaccination for immune recovery following sepsisInfection following recovery from sepsisInfections and InfestationsBacterial sepsisISRCTN11401066Guy's and St Thomas' NHS Foundation Trust214
进行中（未招募）
1 期
Vaccination for immune recovery following sepsisMedDRA version: 20.0 Level: PT Classification code 10040047 Term: Sepsis System Organ Class: 10021881 - Infections and infestationsSepsisEUCTR2017-002236-17-GBGuy's and St Thomas' NHS Foundation Trust214
已完成
4 期
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 YearsHerpes ZosterNCT04869982GlaxoSmithKline6,138
已完成
4 期
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in AdultsPneumonia, PneumococcalPneumococcal Infections13-valent Pneumococcal VaccineNCT00744263Pfizer84,496
已完成
1 期
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)Pneumococcal ImmunizationNCT06698198Sanofi Pasteur, a Sanofi Company175